Key result
SMART registry prospectively evaluates multimodal risk factor management across 500 patients with CAD and PAD.
Why the study?
Coronary artery disease and peripheral arterial disease cause substantial morbidity and mortality in Germany, especially in rural, non-metropolitan areas, prompting the need to evaluate and improve risk factor management.
Cohort (n=500)
Yes
This protocol outlines a prospective registry to evaluate a standardized multimodal risk factor management tool aimed at addressing treatment disparities in rural patients with coronary and peripheral artery disease.
May guide multimodal management in rural CAD/PAD; leaves open efficacy without randomized confirmation.
INTRODUCTION: Coronary artery disease (CAD) and peripheral arterial disease (PAD) account for significant morbidity and mortality in Germany and are more prevalent in rural, non-metropolitan areas. The goal of this study is to screen patients for their current atherosclerotic status, initiate treatment according to the latest scientific findings using a standardised multimodal approach and track their atherosclerotic status over one year. METHODS AND ANALYSIS: This manuscript describes the study protocol of a prospective, multicentre registry of 500 sequential patients with CAD and/or PAD in rural, non-metropolitan regions of Germany. Patients, who visit the "WalkByLab" at the Brandenburg Medical School, Brandenburg, Germany, will be assessed by using our structured, multimodal risk factor management (SMART) tool to evaluate cardiovascular morbidity data, collect information on care and deliver multimodal therapy. The study's primary objective is a cross-sectional examination of the risk profile, diagnostic and therapeutic status in this patient group. Secondary objectives include the assessment of risk factor correlations as well as changes in risk-factor profile and therapy adherence. Patients will be examined at baseline and followed up at three-monthly intervals for one year. Over this time, atherosclerotic risk factors and patient adherence to defined therapeutic strategies will be evaluated. Study completion is estimated to be December 2021. An expansion of this concept into other rural, non-metropolitan neighbouring regions is planned. ETHICS AND DISSEMINATION: This registry was assessed and approved by the ethics committee of the Brandenburg State Medical Association, Brandenburg, Germany, and conducted in accordance with the Declaration of Helsinki. The study findings will be disseminated through usual academic channels including meeting presentations and peer-reviewed publications. PROTOCOL VERSION: 1.0.
No takes yet. Share an insight, caveat, or question.
Zemmrich et al. (2021) conducted a cohort in Coronary artery disease and peripheral arterial disease (n=500). Structured, multimodal risk factor management (SMART) tool was evaluated on Cross-sectional examination of the risk profile, diagnostic and therapeutic status. A structured, multimodal risk factor management (SMART) tool will be prospectively evaluated in a multicenter registry of 500 patients with coronary and peripheral artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: